Trial · NCT04526704
Adverse events144
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 144
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Treatment Continuation Cohort | 7 | 21 | |
| other | COVID-19 | Infections and infestations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 2 | 3 | |
| other | COVID-19 | Infections and infestations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 1 | 11 | |
| other | Upper respiratory tract infection | Infections and infestations | Treatment Continuation Cohort | 4 | 21 | |
| other | Upper respiratory tract infection | Infections and infestations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 0 | 3 | |
| other | Upper respiratory tract infection | Infections and infestations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 0 | 11 | |
| other | Tooth infection | Infections and infestations | Treatment Continuation Cohort | 2 | 21 | |
| other | Tooth infection | Infections and infestations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 0 | 3 | |
| other | Tooth infection | Infections and infestations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 0 | 11 | |
| other | Sinusitis | Infections and infestations | Treatment Continuation Cohort | 0 | 21 | |
| other | Sinusitis | Infections and infestations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 1 | 3 | |
| other | Sinusitis | Infections and infestations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 0 | 11 | |
| other | Blood creatinine phosphokinase increased | Investigations | Treatment Continuation Cohort | 8 | 21 | |
| other | Blood creatinine phosphokinase increased | Investigations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 2 | 3 | |
| other | Blood creatinine phosphokinase increased | Investigations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 2 | 11 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment Continuation Cohort | 5 | 21 | |
| other | Aspartate aminotransferase increased | Investigations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 1 | 3 | |
| other | Aspartate aminotransferase increased | Investigations | Treatment-Free Period of Treatment-Free/Re-treatment Cohort | 0 | 11 | |
| other | Alanine aminotransferase increased | Investigations | Treatment Continuation Cohort | 2 | 21 | |
| other | Alanine aminotransferase increased | Investigations | Re-Treatment Period of Treatment-Free/Re-Treatment Cohort | 1 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04526704/events